Personalized FLT3 Mutated Proliferative Disorder Treatment Platform

A next-generation treatment platform for FLT3 mutated proliferative disorders, integrating theranostics, personalized treatment regimens, and machine learning-driven treatment outcome predictions to revolutionize patient care.

The original patent disclosed the use of crenolanib for treating FLT3 mutated proliferative disorders. However, the current approach has limitations, including the need for manual dosage adjustments and the lack of personalized treatment strategies. The new inventive concept addresses these limitations by introducing a comprehensive platform that leverages advanced diagnostics, machine learning, and precision medicine to provide tailored treatments for individual patients.

The inventive concept comprises a theranostic module that identifies a patient's FLT3 mutation profile, a personalized treatment regimen generator that recommends customized crenolanib-based therapy, and a machine learning-driven treatment outcome prediction system. The platform dynamically adjusts the dosage of crenolanib based on the patient's FLT3 mutation profile over time, ensuring optimal treatment outcomes. Additionally, the platform incorporates a kit for treating FLT3 mutated proliferative disorders, including a container of crenolanib, a companion diagnostic, and instructions for use that incorporate machine learning algorithms.

The new inventive concept introduces a paradigm shift in the treatment of FLT3 mutated proliferative disorders by integrating advanced diagnostics, machine learning, and precision medicine. The novel combination of theranostics, personalized treatment regimens, and dynamic dosage adjustment provides a significant improvement over the current approach, making the original patent's concept obsolete.

Alternative embodiments of the inventive concept could include the integration of additional therapeutic agents, the use of different machine learning algorithms, or the incorporation of real-time patient monitoring data to further optimize treatment outcomes.

The inventive concept has significant commercial potential in the oncology market, particularly in the treatment of FLT3 mutated proliferative disorders. The platform's ability to provide personalized treatment strategies and improve treatment outcomes could lead to increased adoption and market share, with potential applications in other disease areas as well.